Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma

被引:13
作者
Khaledian, Behnoush [1 ,2 ,3 ]
Taguchi, Ayumu [2 ,3 ]
Shin-ya, Kazuo [4 ]
Kondo-Ida, Lisa [1 ,5 ]
Kagaya, Noritaka [4 ]
Suzuki, Motoshi [1 ,6 ]
Kajino, Taisuke [1 ,2 ,3 ]
Yamaguchi, Tomoya [1 ,7 ]
Shimada, Yukako [1 ,2 ,3 ]
Takahashi, Takashi [1 ,8 ]
机构
[1] Nagoya Univ, Grad Sch Med, Div Mol Carcinogenesis, Ctr Neurol Dis & Canc, Nagoya, Aichi, Japan
[2] Aichi Canc Ctr, Div Mol Diagnost, Nagoya, Aichi, Japan
[3] Nagoya Univ, Grad Sch Med, Dept Canc Diagnost & Therapeut, Div Adv Canc Diagnost, Nagoya, Aichi, Japan
[4] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki, Japan
[5] Nagoya Univ, Grad Sch Med, Dept Occupat & Environm Hlth, Nagoya, Aichi, Japan
[6] Fujita Hlth Univ, Sch Med, Div Mol Oncol, Toyoake, Aichi, Japan
[7] Kumamoto Univ, Prior Org Innovat & Excellence, Kumamoto, Japan
[8] Aichi Canc Ctr, Nagoya, Aichi, Japan
基金
日本学术振兴会;
关键词
geldanamycin; HSP90; lung adenocarcinoma; proteasomal degradation; ROR1; RESISTANCE; HSP90; SURVIVAL; CANCER; ONCOGENE; HEAT-SHOCK-PROTEIN-90; GELDANAMYCIN; NKX2-1/TTF-1; EXPRESSION; CHAPERONE;
D O I
10.1111/cas.14786
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have previously identified receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a direct transcriptional target of TTF-1/NKX2-1, a lineage-survival oncogene in lung adenocarcinoma. ROR1 sustains prosurvival signaling from multiple receptor tyrosine kinases including epidermal growth factor receptor, MET, and insulin-like growth factor 1 receptor in part by maintaining the caveolae structure as a scaffold protein of cavin-1 and caveolin-1. In this study, a high throughput screening of the natural product library containing 2560 compounds was undertaken using a cell-based FluoPPI assay detecting ROR1-cavin-1 interaction. As a result, geldanamycin (GA), a known inhibitor of heat shock protein 90 (HSP90), was identified as a potential inhibitor of ROR1. Geldanamycin, as well as two GA derivatives tested in the clinic, 17-allylamino-17-demethoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), decreased ROR1 protein expression. We found that ROR1 physically interacted with HSP90 alpha, but not with other HSP90 paralogs, HSP90 beta or GRP94. Geldanamycin in turn destabilized and degraded ROR1 protein in a dose- and time-dependent manner through the ubiquitin/proteasome pathway, resulting in a significant suppression of cell proliferation in lung adenocarcinoma cell lines, for which the kinase domain of ROR1, but not its kinase activity or N-glycosylation, was required. Our findings indicate that HSP90 is required to sustain expression of ROR1 crucial for lung adenosarcoma survival, suggesting that inhibition of HSP90 could be a promising therapeutic strategy in ROR1-positive lung adenocarcinoma.
引用
收藏
页码:1225 / 1234
页数:10
相关论文
共 44 条
[1]   Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues [J].
Balakrishnan, Ashwini ;
Goodpaster, Tracy ;
Randolph-Habecker, Julie ;
Hoffstrom, Benjamin G. ;
Jalikis, Florencia G. ;
Koch, Lisa K. ;
Berger, Carolina ;
Kosasih, Paula L. ;
Rajan, Anusha ;
Sommermeyer, Daniel ;
Porter, Peggy L. ;
Riddell, Stanley R. .
CLINICAL CANCER RESEARCH, 2017, 23 (12) :3061-3071
[2]   Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia [J].
Bicocca, Vincent T. ;
Chang, Bill H. ;
Masouleh, Behzad Kharabi ;
Muschen, Markus ;
Loriaux, Marc M. ;
Druker, Brian J. ;
Tyner, Jeffrey W. .
CANCER CELL, 2012, 22 (05) :656-667
[3]   The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics [J].
Cheng, Ting-Yuan David ;
Cramb, Susanna M. ;
Baade, Peter D. ;
Youlden, Danny R. ;
Nwogu, Chukwumere ;
Reid, Mary E. .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) :1653-1671
[4]   Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia [J].
Choi, Michael Y. ;
Widhopf, George F., II ;
Ghia, Emanuela M. ;
Kidwell, Reilly L. ;
Hasan, Md Kamrul ;
Yu, Jian ;
Rassenti, Laura Z. ;
Chen, Liguang ;
Chen, Yun ;
Pittman, Emily ;
Pu, Minya ;
Messer, Karen ;
Prussak, Charles E. ;
Castro, Januario E. ;
Jamieson, Catriona ;
Kipps, Thomas J. .
CELL STEM CELL, 2018, 22 (06) :951-+
[5]   Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies [J].
Daneshmanesh, Amir Hossein ;
Porwit, Anna ;
Hojjat-Farsangi, Mohammad ;
Jeddi-Tehrani, Mahmood ;
Tamm, Katja Pokrovskaja ;
Grander, Dan ;
Lehmann, Soren ;
Norin, Stefan ;
Shokri, Fazel ;
Rabbani, Hodjattallah ;
Mellstedt, Hakan ;
Osterborg, Anders .
LEUKEMIA & LYMPHOMA, 2013, 54 (04) :843-850
[6]   Genomic alterations in lung adenocarcinoma [J].
Devarakonda, Siddhartha ;
Morgensztern, Daniel ;
Govindan, Ramaswamy .
LANCET ONCOLOGY, 2015, 16 (07) :E342-E351
[7]   Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal,antigen and receptor for Wnt5a [J].
Fukuda, Tetsuya ;
Chen, Liguang ;
Endo, Tomoyuki ;
Tang, Li ;
Lu, Desheng ;
Castro, Jariuario E. ;
Widhopf, George F., II ;
Rassenti, Laura Z. ;
Cantwell, Mark J. ;
Prussak, Charles E. ;
Carson, Dennis A. ;
Kipps, Thomas J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (08) :3047-3052
[8]   Inhibition of HSP90 molecular chaperones: moving into the clinic [J].
Garcia-Carbonero, Rocio ;
Carnero, Amancio ;
Paz-Ares, Luis .
LANCET ONCOLOGY, 2013, 14 (09) :E358-E369
[9]   Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins [J].
Guix, Marta ;
Faber, Anthony C. ;
Wang, Shizhen Emily ;
Olivares, Maria Graciela ;
Song, Youngchul ;
Qu, Sherman ;
Rinehart, Cammie ;
Seidel, Brenda ;
Yee, Douglas ;
Arteaga, Carlos L. ;
Engelman, Jeffrey A. .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (07) :2609-2619
[10]   First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells [J].
Hojjat-Farsangi, M. ;
Daneshmanesh, A. H. ;
Khan, A. S. ;
Shetye, J. ;
Mozaffari, F. ;
Kharaziha, P. ;
Rathje, L-S ;
Kokhaei, P. ;
Hansson, L. ;
Vagberg, J. ;
Bystrom, S. ;
Olsson, E. ;
Lofberg, C. ;
Norstrom, C. ;
Schultz, J. ;
Norin, M. ;
Olin, T. ;
Osterborg, A. ;
Mellstedt, H. ;
Moshfegh, A. .
LEUKEMIA, 2018, 32 (10) :2291-2295